Clinical Trial: Efficacy of Different Doses of Bezafibrate in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926087) titled 'Efficacy of Different Doses of Bezafibrate in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis' on Nov. 16, 2025.

Brief Summary: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failure. Ursodeoxycholic acid (UDCA) is the first-line treatment; however, up to 40% of patients exhibit an incomplete biochemical response. Bezafibrate (BZF), a pan-PPAR agonist, has shown promising results when combined with UDCA, improving biochemical parameters and symptoms such as pruritus.

This prospective, randomized, open-label controlled study aims ...